Synergistic antidiabetic activities of zinc, cyclo (his-pro), and arachidonic acid.
Previous studies have already shown that prostate extract (PE) has antidiabetic activity when given to animals and humans. In this study, we explore whether this antidiabetic activity is related to the high concentrations of zinc, cyclo (his-pro) (CHP), and the prostaglandin precursor, arachidonic acid (AA), in prostate tissue. When streptozotocin-induced diabetic rats were given drinking water containing 10 mg/L zinc and 100 mg/L PE for 3 weeks, fasting blood glucose levels and glucose clearance rates, but not plasma insulin levels, were significantly lower than at pretreatment. In subsequent experiments, blood glucose levels in rats given PE for 3 weeks were significantly lower than in rats given distilled water or 10 mg/L zinc alone. However, in rats given 100 mg/L CHP with zinc, blood glucose levels were also lower than in rats given PE alone. Time-course studies in diabetic rats given drinking water containing 20 mg/L Zn, 20 mg/L L-histidine, and 10 mg/L CHP showed that blood glucose levels dropped 209 +/- 53 mg/dL in 1 day and stayed low for 2 weeks. When CHP was replaced with 100 mg AA/L, blood glucose levels dropped 230 +/- 64 mg/dL in 5 days, but returned to the original values 11 days later. Growth rate improved and water consumption decreased significantly in CHP- and AA-treated diabetic rats. High intake of L-histidine and testosterone increased blood glucose concentrations in diabetic rats. To determine optimal dosages of CHP and AA, we gave rats drinking water containing 10 mg/L Zn and 0.5 mg/L L-histidine with various concentrations of CHP or AA. The most effective doses for reducing blood glucose levels were 0.32 mg CHP/kg/day and 11 mg AA/kg/day. These data suggest that the active antidiabetic ingredients in the PE are CHP, zinc, and AA or its precursors.
Song
M K
MK
Department of Pediatrics, Center for Human Nutrition, UCLA School of Medicine, Los Angeles, CA 90095-1742, USA.
Rosenthal
M J
MJ
Hong
S
S
Harris
D M
DM
Hwang
I
I
Yip
I
I
Golub
M S
MS
Ament
M E
ME
Go
V L
VL
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D016718:Arachidonic Acid / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects; D002457:Cell Extracts / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D004285:Dogs; D004357:Drug Synergism; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000502:physiology; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011467:Prostate / Q000737:chemistry*; D051381:Rats; D013311:Streptozocin; D015032:Zinc / Q000627:therapeutic use
D000975:Antioxidants; D001786:Blood Glucose; D002457:Cell Extracts; D007004:Hypoglycemic Agents; D007328:Insulin; D010456:Peptides, Cyclic; D010879:Piperazines; D016718:Arachidonic Acid; D013311:Streptozocin; D015032:Zinc; C015924:histidyl-proline diketopiperazine